We serve Chemical Name:4-bromo-2,6-difluorobenzamide CAS:840481-49-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-bromo-2,6-difluorobenzamide
CAS.NO:840481-49-4
Synonyms:Benzamide,4-bromo-2,6-difluoro
Molecular Formula:C7H4BrF2NO
Molecular Weight:236.01400
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:44.08000
Exact Mass:234.94400
LogP:2.71040
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzamide,4-bromo-2,6-difluoro chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzamide,4-bromo-2,6-difluoro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzamide,4-bromo-2,6-difluoro Use and application,Benzamide,4-bromo-2,6-difluoro technical grade,usp/ep/jp grade.
Related News: “His strong track record of success and deep experience of fast-moving consumer goods and consumer health, proven at P&G, Novartis and GSK, means he is the right choice” to lead the consumer health unit as an independent company, GSK Chairman Jonanthan Symonds said of McNamara in the statement. 2-amino-3-hydroxy-4-phosphonooxy-butanoic acid manufacturers The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo. Methylenetetrahydrofolate dehydrogenase (Anaplasma marginalestrain St. Maries gene folD) suppliers It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. 2-(4-methoxy)-phenyl-butyronitrile vendor & factory “His strong track record of success and deep experience of fast-moving consumer goods and consumer health, proven at P&G, Novartis and GSK, means he is the right choice” to lead the consumer health unit as an independent company, GSK Chairman Jonanthan Symonds said of McNamara in the statement.,The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo.
